FrancophonIA/ELRC3.0 huggingface dataset:
English: CYP3A4 is the major enzyme responsible for ticagrelor metabolism and the formation of the active metabolite and their interactions with other CYP3A substrates ranges from activation through to inhibition.
Croatian: CYP3A4 je glavni enzim odgovoran za metabolizam tikagrelora i formiranje aktivnog metabolita, i njihove interakcije s drugim supstratima CYP3A variraju od aktivacije do inhibicije.
English: This is because of the increased risk of bleeding.
Croatian: Ovo se odnosi na povećani rizik od krvarenja.
English: Brilique in combination with acetylsalicylic acid (another antiplatelet agent) is to be used in adults only.
Croatian: Brilique, u kombinaciji s acetilsalicilatnom kiselinom (još jednim antitrombocitnim lijekom), primjenjuje se samo kod odraslih.
English: PLATO Minor: Requires medical intervention to stop or treat bleeding.
Croatian: PLATO manja: Zahtijeva medicinsku intervenciju za zaustavljanje ili liječenje krvarenja.
English: Patients in PLATO receiving ticagrelor took a variety of statins, with no concern of an association with statin safety among the 93% of the PLATO cohort taking these medicinal products.
Croatian: Bolesnici u studiji PLATO koji su primali tikagrelor uzimali su različite statine, bez vođenja računa o povezanosti sa sigurnošću primjene statina u 93% kohorte PLATO-a koja je uzimala ove lijekove.
English: Although the efficacy profiles of 90 mg and 60 mg were similar, there is evidence that the lower dose has a better tolerability and safety profile in relation to risk of the bleeding and dyspnoea.
Croatian: Iako su profili djelotvornosti za doze od 90 mg i 60 mg bili slični, postoje dokazi da se niža doza bolje podnosi i ima bolji sigurnosni profil s obzirom na rizik od krvarenja i dispneje.
English: In PLATO, 42% of the 1584 patients (12% of cohort) who underwent coronary artery bypass graft (CABG) surgery had a PLATO Major Fatal/Life-threatening bleeding with no difference between treatment groups.
Croatian: U studiji PLATO, 42% od 1584 bolesnika (12% kohorte) koji su bili podvrgnuti operaciji aortokoronarne premosnice (CABG) imali su PLATO veliko fatalno/krvarenje koje ugrožava život bez razlike između liječenih skupina.
English: Do not use this medicine after the expiry date which is stated on the blister and carton after EXP.
Croatian: Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i blisteru iza oznake „EXP“.
English: • You have an increased risk of bleeding because of: - a recent serious injury - recent surgery (including dental work, ask your dentist about this) - you have a condition that affects blood clotting - recent bleeding from your stomach or gut (such as a stomach ulcer or colon ‘polyps')
Croatian: • Imate povećani rizik od krvarenja zbog: - nedavne ozbiljne ozljede - nedavne operacije (uključujući i zahvate kod zubara, upitajte o tome svog zubara) - ako imate neko stanje koje utječe na zgrušavanje krvi - ako ste nedavno imali krvarenje u želucu ili crijevima (na primjer, zbog čira u želucu ili polipa na debelom crijevu)
English: PLATO included patients with baseline congestive heart failure, COPD or asthma; these patients, and the elderly, were more likely to report dyspnoea.
Croatian: Studija PLATO je uključivala bolesnike s kongestivnim zatajenjem srca, KOPB-om ili astmom; ovi bolesnici kao i stariji ispitanici su vjerojatnije prijavljivati dispneju.
English: The metabolite parent ratios are 0.28 for Cmax and 0.42 for AUC.
Croatian: Omjeri metabolita i polazne tvari su 0,28 za Cmax i 0,42 za AUC.
English: Similar to the overall PLATO study, total PLATO Major bleeding did not differ between ticagrelor and clopidogrel, regardless of CYP2C19 or ABCB1 genotype.
Croatian: Slično kao i u ukupnoj studiji PLATO, ukupno veliko krvarenje u studiji PLATO se nije razlikovalo između tikagrelora i klopidogrela, bez obzira na genotip CYP2C19 i ABCB1.
English: • Patients with concomitant administration of medicinal products that may increase the risk of bleeding (e.g. non-steroidal anti-inflammatory drugs (NSAIDs), oral anticoagulants and/or fibrinolytics) within 24 hours of ticagrelor dosing.
Croatian: • Bolesnici koji istodobno uzimaju lijekove koji mogu povećati rizik od krvarenja (npr. ne-steroidni protuupalni lijekovi (NSAID), oralni antikoagulansi i/ili fibrinolitici) unutar 24 sata od uzimanja tikagrelora.
English: • A similar effect on other statins metabolised by CYP3A4 cannot be excluded.
Croatian: • Ne može se isključiti sličan učinak na druge statine koje metabolizira CYP3A4.
English: If you are in the hospital you may be given this tablet mixed with some water and given through a tube via the nose (nasogastric tube).
Croatian: Ako ste u bolnici, ovu tabletu možete dobiti pomješanu s malo vode putem cijevi kroz nos (nazogastrična cijev).
English: No clinically relevant effect on oral contraceptive efficacy is expected when levonorgestrel and ethinyl estradiol are co-administered with ticagrelor.
Croatian: Ne očekuje se klinički značajan učinak na djelotvornost oralnog kontraceptiva kada se levonorgestrel i etinilestradiol istodobno primjenjuju s tikagrelorom.
English: When the orodispersible tablet was dispersed in saliva and swallowed with water, ticagrelor AUC was similar, while Cmax was about 15% lower than for the film-coated tablet.
Croatian: Kada su raspadljive tablete za usta bile otopljene u slini i progutane s vodom, AUC tikagrelora bio je sličan, dok je Cmax bio oko 15% niži nego kod filmom obloženih tableta.
English: The higher incidence of dyspnoea with ticagrelor is not associated with new or worsening heart or lung disease (see section 4.4).
Croatian: Veća učestalost dispneje s tikagrelorom nije povezana s novim ili pogoršanim srčanom ili plućnom bolešću (vidjeti dio 4.4).
English: These increases are not considered clinically significant.
Croatian: Ova povećanja ne smatraju se klinički značajnima.
English: Minor Bleed: Requires medical intervention to stop or treat bleeding.
Croatian: Manje krvarenje: Zahtijeva medicinsku intervenciju za zaustavljanje ili liječenje krvarenja.
English: A 60 mg orodispersible tablet is not available.
Croatian: Raspadljiva tableta za usta od 60 mg nije dostupna.
English: • Selective Serotonin Reuptake Inhibitors (abbreviated as SSRIs) taken as antidepressants such as paroxetine, sertraline and citalopram.
Croatian: • selektivni inhibitori ponovne pohrane serotonina (skraćeno SSRI) koji se uzimaju kao antidepresivi, kao što su paroksetin, sertralin i citalopram.
English: The small difference in Cmax noted is unlikely to be of clinical relevance.
Croatian: Malo je vjerojatno da je zapažena mala razlika u Cmax od kliničkog značaja.
English: However, more PLATO combined Major + Minor bleeding occurred with ticagrelor compared with clopidogrel.
Croatian: Međutim, više se PLATO kombiniranih velikih + manjih krvarenja dogodilo sa tikagrelorom u usporedbi s klopidogrelom.
English: If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking this medicine.
Croatian: Ako se bilo što od gore navedenog odnosi na Vas (ili niste sigurni da li se odnosi na Vas), obratite se svom liječniku ili ljekarniku prije nego što počnete uzimati ovaj lijek.
English: You may be at increased risk of bleeding.
Croatian: Mogli biste biti izloženi povećanom riziku od krvarenja.
English: This is related to inhibition of the P2Y12-receptor on the healthy donor platelets in the test by ticagrelor in the patient's sera/plasma.
Croatian: To je povezano s inhibicijom receptora P2Y12 na trombocitima zdravih darivatelja u testu uslijed djelovanja tikagrelora u serumu/plazmi bolesnika.
English: The mean trough digoxin levels were increased about 30% with ticagrelor co-administration with some individual maximum increases to 2-fold.
Croatian: Srednje vrijednosti najnižih razina digoksina bile su povećane oko 30% kod istodobne primjene tikagrelora s pojedinim individualnim maksimalnim povećanjima do dva puta.
English: • the clot can cut off the blood supply completely; this can cause a heart attack (myocardial infarction) or stroke, or
Croatian: • ugrušak može zaustaviti dotok krvi u potpunosti; što može uzrokovati srčani udar (infarkt miokarda) ili moždani udar, ili
English: Higher exposures to ticagrelor and the active metabolite were observed in women compared to men.
Croatian: Veća je izloženost tikagreloru i aktivnom metabolitu uočena u žena nego u muškaraca.
English: CALENDAR BLISTER
Croatian: KALENDARSKI BLISTER
English: Ticagrelor reduced the occurrence of the primary composite endpoint compared to clopidogrel in both the UA/NSTEMI and STEMI population (Table 4).
Croatian: Tikagrelor je smanjio pojavljivanje primarne složene mjere ishoda u usporedbi s klopidogrelom u obje populacije nestabilne angine/NSTEMI i STEMI (tablica 4).
English: Chronic daily ASA doses to accompany ticagrelor should be 75-150 mg (see sections 4.2 and 4.4).
Croatian: Kronične dnevne doze acetilsalicilatne kiseline uz tikagrelor trebale bi iznositi 75 - 150 mg (vidjeti dio 4.2 i 4.4).
English: To study the occurrence of ventricular pauses and other arrhythmic episodes during PLATO, investigators performed Holter monitoring in a subset of nearly 3000 patients, of whom approximately 2000 had recordings both in the acute phase of their ACS and after one month.
Croatian: Kako bi proučili pojavljivanje ventrikularnih stanki i drugih aritmijskih epizoda tijekom studije PLATO, istraživači su izvršili promatranje Holterom na podskupini od skoro 3000 bolesnika od kojih je približno 2000 imalo očitanja i u akutnoj fazi njihovog akutnog koronarnog sindroma i nakon jednog mjeseca.
English: • Vaginal bleeding that is heavier, or happens at different times, than your normal period
Croatian: • Vaginalno krvarenje koje je obilnije ili se događa izvan normalnog menstrualnog ciklusa
English: These differences are not considered clinically significant.
Croatian: Ove se razlike ne smatraju klinički značajnima.
English: If you forget to take Brilique
Croatian: Ako ste zaboravili uzeti Brilique
English: The mixture can also be administered via a nasogastric tube (CH8 or greater).
Croatian: Smjesa se može također primijeniti pomoću nazogastrične cijevi (CH8 ili veće).
English: Ticagrelor is also a P-glycoprotein (P-gp) substrate and a weak P-gp inhibitor and may increase the exposure of P-gp substrates.
Croatian: Tikagrelor je također supstrat P-glikoproteina (P-gp) i slabi inhibitor P-gp-a, te može povećati izloženost supstratima
English: Discontinuation of treatment due to non-procedural bleeding was more common for ticagrelor (2.9%) than for clopidogrel (1.2%; p<0.001).
Croatian: Prekid liječenja zbog neproceduralnog krvarenja je bio češći za tikagrelor (2,9%) nego za klopidogrel (1,2%; p<0,001).
English: If you are not sure, talk to your doctor or pharmacist before taking this medicine.
Croatian: Ako niste sigurni, obratite se liječniku ili ljekarniku prije nego što počnete uzimati ovaj lijek.
English: • phenytoin, carbamazepine and phenobarbital (used to control seizures)
Croatian: • fenitoin, karbamazepin i fenobarbital (za kontrolu epileptičkih napadaja),
English: Fatal CABG bleeding occurred in 6 patients in each treatment group (see section 4.4).
Croatian: Do fatalnog krvarenja u ispitanika s CABG-om došlo je u po 6 ispitanika u svakoj liječenoj skupini (vidjeti dio 4.4).
English: Holter ECG monitoring has shown an increased frequency of mostly asymptomatic ventricular pauses during treatment with ticagrelor compared with clopidogrel.
Croatian: Holter ECG monitoring) pokazalo je povećanu učestalost pretežno asimptomatskih ventrikularnih pauza tijekom liječenja s tikagrelorom u usporedbi s klopidogrelom.
English: Overall outcome of bleeding rates in the PLATO study are shown in Table 2.
Croatian: Ukupni ishod učestalosti krvarenja u studiji PLATO je prikazan u tablici 2.
English: There was no evidence of benefit (no reduction in the primary composite endpoint of CV death, MI and stroke, but an increase in major bleeding) when ticagrelor 60 mg twice daily was introduced in clinically stable patients >2 years from the MI, or more than one year after stopping previous ADP receptor inhibitor treatment (see also section 4.2).
Croatian: Nije bilo dokaza o koristi (bez smanjenja primarnog kompozitnog ishoda kadriovaskularne smrti, IM i moždanog udara, ali povećanje velikog krvarenja) kada se tikagrelor u dozi od 60 mg dvaput dnevno primjenjivao u klinički stabilnih bolesnika koji su imali IM prije >2 godine, ili više od godinu dana nakon prekida liječenja prethodnim inhibitorom ADP receptora (također vidjeti dio 4.2).
English: Very common (may affect more than 1 in 10 people)
Croatian: Vrlo često (može se javiti u više od 1 na 10 osoba)
English: If you take more Brilique than you should, talk to a doctor or go to hospital straight away.
Croatian: Ako ste uzeli veću dozu lijeka Brilique nego što Vam je liječnik propisao, posavjetujte se s liječnikom ili odmah otiđite u bolnicu.
English: In the event of an overdose, the above potential adverse reactions could occur and ECG monitoring should be considered.
Croatian: U slučaju predoziranja, mogu se pojaviti gore navedene nuspojave, pa treba razmisliti o praćenju EKG-a.
English: Therefore, appropriate clinical and/or laboratory monitoring is recommended when giving narrow therapeutic index P-gp dependent medicinal products like digoxin concomitantly with ticagrelor.
Croatian: Stoga se preporučuje odgovarajuće kliničko i/ili laboratorijsko praćenje kada se lijekovi uske terapijske širine koji ovise o P-gp, kao što je digoksin, daju istodobno s tikagrelorom.
English: This imbalance did not occur at one month: 2.0% versus 2.1% for ticagrelor patients with and without CHF history, respectively; and 3.8% versus 1.4% with clopidogrel.
Croatian: Ova se neravnoteža nije pojavila u roku jednog mjeseca: 2,0% u odnosu na 2,1% za ispitanike s tikagrelorom sa i bez anamneze KZS; te 3,8% u odnosu na 1,4% za ispitanike s klopidogrelom.
English: Since co-administration of ticagrelor with desmopressin did not decrease template-bleeding time, desmopressin is unlikely to be effective in managing clinical bleeding events (see section 4.5).
Croatian: Budući da istodobna primjena tikagrelora s dezmopresinom nije smanjila vrijeme krvarenja, malo je vjerojatno da je dezmopresin učinkovit u zbrinjavanju slučajeva klinički značajnih krvarenja (vidjeti dio 4.5).
English: More patients had ventricular pauses with ticagrelor (6.0%) than with clopidogrel (3.5%) in the acute phase; and 2.2% and 1.6%, respectively, after 1 month (see section 4.4).
Croatian: Više bolesnika imalo je ventrikularne pauze s tikagrelorom (6,0%) nego s klopidogrelom (3,5%) u akutnoj fazi; i 2,2% odnosno 1,6% nakon mjesec dana (vidjeti dio 4.4).
English: The Cmax of the active metabolite was unchanged and the AUC was decreased by 46%, respectively.
Croatian: Cmax aktivnog metabolita je bio nepromijenjen a AUC je smanjen za 46%.
English: Cyclosporine (P-gp and CYP3A inhibitor)
Croatian: Ciklosporin (inhibitor P-gp-a i CYP3A)
English: The expected effect of excessive ticagrelor dosing is prolonged duration of bleeding risk associated with platelet inhibition.
Croatian: Očekivani učinak prekomjerne doze tikagrelora je produljeno trajanje rizika od krvarenja povezano s inhibicijom trombocita.
English: Mean serum uric acid increased approximately 15% with ticagrelor compared to approximately 7.5% with clopidogrel and after treatment was stopped, decreased to approximately 7% on ticagrelor but with no decrease observed for clopidogrel.
Croatian: Srednja koncentracija uratne kiseline u serumu povećana je za oko 15% s tikagrelorom u odnosu na oko 7,5% s klopidogrelom, a nakon prekida liječenja smanjena je na oko 7% za tikagrelor, ali smanjenje nije primijećeno za klopidogrel.
English: In female rats, ticagrelor at high dose showed an increased incidence of uterine tumours (adenocarcinomas) and an increased incidence of hepatic adenomas.
Croatian: Kod ženki štakora, tikagrelor je pri visokim dozama pokazao povećanu incidenciju tumora maternice (adenokarcinoma) i povećanu incidenciju adenoma jetre.
English: Platelet transfusion did not reverse the antiplatelet effect of ticagrelor in healthy volunteers and is unlikely to be of clinical benefit in patients with bleeding.
Croatian: Transfuzija trombocita nije poništila antitrombotsko djelovanje tikagrelora u zdravih dobrovoljaca i malo je vjerojatno da će biti od kliničke koristi u bolesnika sa krvarenjem.
English: Based on a relationship observed in PLATO between maintenance ASA dose and relative efficacy of ticagrelor compared to clopidogrel, co-administration of ticagrelor and high maintenance dose ASA (>300 mg) is not recommended (see section 5.1).
Croatian: Prema odnosu uočenom u studiji PLATO između doze održavanja acetilsalicilatne kiseline i relativne djelotvornosti tikagrelora u usporedbi s klopidogrelom, istodobna primjena tikagrelora i visoke doze održavanja acetilsalicilatne kiseline (> 300 mg) se ne preporučuje (vidjeti dio 5.1).
English: • Feeling short of breath - this is very common.
Croatian: • Nedostatak zraka - vrlo česta nuspojava.
English: The formation of the major circulating metabolite AR-C124910XX (also active) from ticagrelor is rapid with a median tmax of approximately 2.5 hours.
Croatian: Stvaranje glavnog cirkulirajućeg metabolita AR-C124910XX (također aktivnog) iz tikagrelora odvija se brzo s medijanom tmax od približno 2,5 sati.
English: Nominal significance value; all others are formally statistically significant by pre-defined hierarchical testing.
Croatian: Ukupni IM uključuje tihi (subklinički) IM, a za datum događaja uzima se datum otkrivanja događaja. nominalna vrijednost značaja; svi drugi su formalno statistički značajni u prethodno definiranom hijerarhijskom testiranju.
English: • Internal bleeding, this may cause dizziness or light-headedness
Croatian: • Unutarnje krvarenje, koje može uzrokovati omaglicu ili ošamućenost
English: In rats, minor developmental anomalies were seen at a maternal toxic dose (safety margin of 5.1).
Croatian: Kod štakora su manje razvojne anomalije uočene pri toksičnoj dozi za majku (granica sigurnosti primjene od 5,1).
English: The tablet can also be dispersed in water and administered via a nasogastric tube (CH8 or greater).
Croatian: Također, tableta se također može rastopiti u vodi i primijeniti pomoću nazogastrične cijevi (CH8 ili veće).
English: • Signs of bleeding such as: - bleeding that is severe or that you cannot control - unexpected bleeding or bleeding that lasts a long time - pink, red or brown urine - vomiting red blood or your vomit looks like ‘coffee grounds' - red or black stools (look like tar) - coughing up or vomiting blood clots
Croatian: • Znakovi krvarenja poput: - teško krvarenje ili krvarenje koje ne možete kontrolirati - neočekivano ili dugotrajno krvarenje - urin roze, crvene ili smeđe boje - povraćanje crvene krvi ili Vaš sadržaj povraćanja izgleda kao „mljevena kava“ - crvena ili crna stolica (izgleda kao katran) - iskašljavanje ili povraćanje krvnih ugrušaka
English: Clopidogrel 75 mg once daily (% patients with event) N=9291
Croatian: Klopidogrel 75 mg jedanput dnevno (% bolesnika s događajem) N=9291
English: Age, sex, weight, race, geographic region, concurrent conditions, concomitant therapy and medical history, including a previous stroke or transient ischaemic attack, all did not predict either overall or non-procedural PLATO Major bleeding.
Croatian: Dob, spol, tjelesna težina, rasa, zemljopisna regija, komorbiditeti, istodobna terapija i povijest bolesti, uključujući prethodni moždani udar i tranzitornu ishemijsku ataku, ništa od navedenog nije moglo predvidjeti ukupno ili ne-proceduralno krvarenje u ispitivanju PLATO.
English: In 2.2% of patients taking ticagrelor and by 0.6% taking clopidogrel investigators considered the dyspnoea causally related to treatment in the PLATO study and few were serious (0.14% ticagrelor; 0.02% clopidogrel), (see section 4.4).
Croatian: Kod 2,2% bolesnika koji su primali tikagrelor i kod 0,6% koji su primali klopidogrel ispitivači su smatrali da je dispneja uzročno povezana s terapijom u studiji PLATO, a nekoliko dispneja je bilo ozbiljno (0,14% tikagrelor; 0,02% klopidogrel), (vidjeti dio 4.4).
English: Table 2 - Analysis of overall bleeding events, Kaplan-Meier estimates at 12 months (PLATO)
Croatian: Tablica 2 - Analiza sveukupnih događaja krvarenja, Kaplan-Meierova procjena nakon 12 mjeseci (PLATO)
English: There is currently no known antidote to reverse the effects of ticagrelor, and ticagrelor is not dialysable (see section 5.2).
Croatian: Trenutno nema poznatog antidota koji može poništiti učinke tikagrelora i tikagrelor se ne može dijalizirati (vidjeti dio 5.2).
English: The primary route of elimination for the active metabolite is most likely via biliary secretion.
Croatian: Primarni put eliminacije aktivnog metabolita je najvjerojatnije izlučivanje preko žuči.
English: Ticagrelor has no or negligible influence on the ability to drive and use machines.
Croatian: Tikagrelor ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
English: It is important to flush the nasogastric tube through with water after administration of the mixture.
Croatian: Važno je isprati nazogastričnu cijev s vodom nakon primjene smjese.
English: • Signs of a blood clotting problem called Thrombotic Thrombocytopenic Purpura (TTP) such as: - fever and purplish spots (called purpura) on the skin or in the mouth, with or without yellowing of the skin or eyes (jaundice), unexplained extreme tiredness or confusion
Croatian: • Znakovi poteškoća u zgrušavanju krvi nazvani trombotična trombocitopenična purpura (TTP) poput: - vrućica i crvene točkice na koži ili u ustima (purpura), sa ili bez žute boje kože ili očiju (žutica), neobjašnjivog teškog umora ili smetenosti
English: Table 3 - Analysis of overall bleeding events, Kaplan-Meier estimates at 36 months (PEGASUS)
Croatian: Tablica 3 - Analiza sveukupnih događaja krvarenja, Kaplan-Meireova procjena nakon 36 mjeseci (PEGASUS)
English: The European Medicines Agency has waived the obligation to submit the results of studies with Brilique in all subsets of the paediatric population in acute coronary syndromes (ACS) and history of myocardial infarction (MI) (see section 4.2 for information on paediatric use).
Croatian: Europska agencija za lijekove izuzela je obvezu podnošenja rezultata ispitivanja lijeka Brilique u svim podskupinama pedijatrijske populacije s akutnim koronarnim sindromom ili infarktom miokarda u anamnezi (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
English: Due to observations of mostly asymptomatic ventricular pauses and bradycardia, caution should be exercised when administering ticagrelor concomitantly with medicinal products known to induce bradycardia (see section 4.4).
Croatian: Budući da su primijećene većinom asimptomatske ventrikularne pauze i bradikardija potreban je oprez pri primjeni tikagrelora istodobno s lijekovima za koje je poznato da potiču bradikardiju (vidjeti dio 4.4).
English: The Cmax and AUC of the active metabolite were reduced by 89% and 56%, respectively.
Croatian: Cmax i AUC aktivnog metabolita smanjeni su za 89%, odnosno 56%.
English: Thrombotic Thrombocytopenic Purpura (TTP) has been reported very rarely with the use of ticagrelor.
Croatian: Trombotična trombocitopenična purpura (TTP) zabilježena je vrlo rijetko nakon primjene tikagrelora.
English: • Bleeding into the brain or inside the skull is an uncommon side effect, and may cause signs of a stroke such as: - sudden numbness or weakness of your arm, leg or face, especially if only on one side of the body - sudden confusion, difficulty speaking or understanding others - sudden difficulty in walking or loss of balance or co-ordination - suddenly feeling dizzy or sudden severe headache with no known cause
Croatian: • Krvarenje u mozgu ili unutar lubanje manje je česta nuspojava, a može uzrokovati znakove moždanog udara kao što su: - iznenadna utrnulost ili slabost ruke, noge ili lica, osobito ako se pojavi samo na jednoj strani tijela - iznenadna smetenost, poteškoće pri govoru ili razumijevanju drugih - iznenadne teškoće u hodanju, gubitak ravnoteže ili koordinacije - iznenadan osjećaj omaglice ili iznenadna jaka glavobolja bez poznatog uzroka